Kalaris Therapeutics Inc. (NASDAQ:KLRS) Stock Has Average Target Price of $18.75

Kalaris Therapeutics Inc. (NASDAQ:KLRS) has received a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $18.75.

A number of equities analysts recently commented on KLRS shares. Wall Street Zen cut shares of Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 13th. Weiss Ratings lowered shares of Kalaris Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday.

Institutional Investors Weigh In On Kalaris Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Sigma Planning Corp bought a new position in Kalaris Therapeutics during the 2nd quarter worth approximately $41,000. WealthTrust Asset Management LLC purchased a new position in Kalaris Therapeutics in the 1st quarter worth approximately $72,000. Velan Capital Investment Management LP lifted its position in Kalaris Therapeutics by 38.9% in the second quarter. Velan Capital Investment Management LP now owns 25,000 shares of the company’s stock valued at $102,000 after purchasing an additional 7,000 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Kalaris Therapeutics in the second quarter valued at approximately $122,000. Finally, Stonepine Capital Management LLC purchased a new stake in shares of Kalaris Therapeutics during the second quarter valued at approximately $122,597. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Kalaris Therapeutics Stock Performance

KLRS stock opened at $1.87 on Tuesday. The company has a market capitalization of $44.52 million, a PE ratio of -0.93 and a beta of 0.42. Kalaris Therapeutics has a one year low of $1.87 and a one year high of $11.88. The company’s 50 day moving average price is $3.15 and its two-hundred day moving average price is $4.23.

Kalaris Therapeutics (NASDAQ:KLRS) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. On average, research analysts predict that Kalaris Therapeutics will post -1.99 EPS for the current year.

Kalaris Therapeutics Company Profile

Kalaris Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for retinal vascular diseases, a group of eye conditions that can lead to vision loss. The company’s research is aimed at addressing diseases in which abnormal blood-vessel growth or leakage damages the retina.

Kalaris Therapeutics’ lead investigational product candidate is KAL-101, an experimental therapy being developed for retinal diseases. The company is advancing KAL-101 through clinical development and evaluating its potential to provide a treatment option for patients with conditions requiring ongoing management of retinal vascular abnormalities.

The company’s activities primarily center on research, clinical development, and the potential commercialization of ophthalmic medicines.